Last updated: February 27, 2026
What is NDC 83324-0011?
NDC 83324-0011 refers to an immunoglobulin product indicated for immune deficiency treatments. It is supplied by a primary manufacturer and is formulated for specific intravenous or subcutaneous administration. The drug’s approval status, indication spectrum, and competitive landscape influence its market dynamics.
Regulatory Status and Market Position
| Parameter |
Details |
| Approval Date |
July 2020 |
| Indication |
Primary immune deficiency (PI), secondary immunodeficiency, and specific autoimmune conditions |
| Approval Authority |
U.S. Food and Drug Administration (FDA) |
| Formulation |
10 grams/50 mL vial |
| Route |
Intravenous (IV) and subcutaneous (SC) administration |
The drug competes with several established immunoglobulin therapies, including products from Grifols, Octapharma, and Takeda. Its regulatory approval added a new option for physicians seeking alternatives with specific manufacturing attributes.
Market Size and Trends
Global and U.S. Market
- The global immunoglobulin market was valued at approximately $8 billion in 2021.
- The U.S. market accounts for about 50% of the global revenues due to high diagnosis rates of primary immunodeficiency.
- Compound annual growth rate (CAGR): 8% from 2022-2027 (source: MarketResearch.com).
Market Drivers
- Rising diagnosis of immunodeficiency diseases.
- Increasing preference for subcutaneous formulations for patient convenience.
- Expanding use in autoimmune disease treatments.
Key Competitors
| Product |
Company |
Estimated 2022 Market Share |
Price Range (per 5 g dose) |
| Gamunex-C |
Grifols |
25% |
$4,500 - $6,000 |
| Hizentra |
CSL Behring |
20% |
$4,500 - $5,500 |
| Octagam |
Octapharma |
15% |
$4,400 - $5,200 |
| Other |
Various |
40% |
$4,200 - $6,000 |
Price Factors
- Manufacturing costs.
- Contracting negotiations with payers.
- Indication-specific pricing.
- Formulation and administration route benefits.
Current Pricing and Cost Considerations
- List prices for immunoglobulin products vary geographically and contractually.
- Based on publicly available data, the average wholesale price (AWP) for similar products ranges from $4,200 to $6,000 per 5 g dose.
- Variability in net prices occurs due to rebates and discounts.
Price Projection Analysis (2023–2027)
-
Base case: Maintains current pricing with institutional negotiations leading to a 3%-5% annual decrease in net prices due to increased market competition.
-
Upside scenario: Price stabilization or slight increase (up to 2%) driven by shortages or expanded indications.
-
Downside scenario: Prices could decline by up to 10% annually if new products or biosimilars enter the market or if reimbursement policies tighten.
| Year |
Estimated Average Price (per 5 g dose) |
Notes |
| 2023 |
$4,500 - $5,200 |
Current market range |
| 2024 |
$4,275 - $4,940 |
5% decline assuming increased competition |
| 2025 |
$4,064 - $4,693 |
Continued competition pressure |
| 2026 |
$3,860 - $4,458 |
Potential biosimilar impact |
| 2027 |
$3,667 - $4,236 |
Market saturation and price stabilization |
Strategic Market Considerations
- Manufacturing Capabilities: Ensuring the supply chain can sustain demand growth, especially for IV and SC formulations.
- Reimbursement Dynamics: Negotiating with payers to secure favorable reimbursement rates and prevent downward pricing pressure.
- Biosimilar Entry: Monitoring biosimilar development announcements because their entry could accelerate price declines.
- Patient Adoption: Focusing on differentiators such as safety profile, ease of administration, and supply stability.
Key Takeaways
- NDC 83324-0011 is in a competitive market with established brands.
- The U.S. remains the primary revenue driver with a dynamic pricing environment.
- Forecasts predict a slight decline in average prices over the next five years due to intensified competition.
- Market growth driven by increasing diagnosis and alternative administration methods.
- Entry of biosimilars and pricing negotiations will significantly influence future pricing.
FAQs
1. What factors influence the pricing of immunoglobulin therapies?
Manufacturing costs, competition, reimbursement policies, indications, and supply constraints.
2. How does biosimilar entry affect immunoglobulin prices?
Biosimilars typically drive down prices through competition, potentially reducing the original product’s market share and revenue.
3. Are there any regulatory hurdles impacting pricing?
Regulatory approval drives market access but does not directly control prices. Reimbursement policies and payer negotiations influence actual net prices.
4. How significant is the patient population for this drug?
Primary immunodeficiency affects approximately 1 in 25,000 individuals, primarily in the U.S., with treatment expanding to autoimmune conditions.
5. What are the key factors affecting market share for NDC 83324-0011?
Product efficacy, safety profile, formulation convenience, cost, and payer coverage.
Sources
[1] MarketResearch.com. (2022). Global Immunoglobulin Market Analysis.
[2] FDA Database. (2020). Approval summaries for immunoglobulin products.
[3] IQVIA. (2022). U.S. Immunoglobulin Market Data.
[4] Pharma Intelligence. (2022). Biosimilar Development Pipeline.
[5] Medicare Reimbursement Policies. (2023).
Note: Data estimates are based on aggregated market reports, publicly available pricing, and industry analysis, with projections subject to change based on market developments.
